AN OBSERVATIONAL STUDY OF AVASTIN® (BEVACIZUMAB) AS FIRST LINE THERAPY IN PATIENTS WITH ADVANCED OVARIAN CANCER (OSCAR 1) First published 24/07/2015 Last updated 02/07/2024 EU PAS number:EUPAS10394 Study Finalised